vs

Side-by-side financial comparison of COMSCORE, INC. (SCOR) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

COMSCORE, INC. is the larger business by last-quarter revenue ($93.5M vs $62.5M, roughly 1.5× TREACE MEDICAL CONCEPTS, INC.). COMSCORE, INC. runs the higher net margin — 3.2% vs -15.0%, a 18.3% gap on every dollar of revenue. On growth, COMSCORE, INC. posted the faster year-over-year revenue change (-1.5% vs -9.0%). COMSCORE, INC. produced more free cash flow last quarter ($2.9M vs $-10.4M). Over the past eight quarters, TREACE MEDICAL CONCEPTS, INC.'s revenue compounded faster (10.6% CAGR vs 3.8%).

Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

SCOR vs TMCI — Head-to-Head

Bigger by revenue
SCOR
SCOR
1.5× larger
SCOR
$93.5M
$62.5M
TMCI
Growing faster (revenue YoY)
SCOR
SCOR
+7.5% gap
SCOR
-1.5%
-9.0%
TMCI
Higher net margin
SCOR
SCOR
18.3% more per $
SCOR
3.2%
-15.0%
TMCI
More free cash flow
SCOR
SCOR
$13.4M more FCF
SCOR
$2.9M
$-10.4M
TMCI
Faster 2-yr revenue CAGR
TMCI
TMCI
Annualised
TMCI
10.6%
3.8%
SCOR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SCOR
SCOR
TMCI
TMCI
Revenue
$93.5M
$62.5M
Net Profit
$3.0M
$-9.4M
Gross Margin
41.0%
80.6%
Operating Margin
7.0%
-9.5%
Net Margin
3.2%
-15.0%
Revenue YoY
-1.5%
-9.0%
Net Profit YoY
-3.7%
-1775.0%
EPS (diluted)
$9.50
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SCOR
SCOR
TMCI
TMCI
Q4 25
$93.5M
$62.5M
Q3 25
$88.9M
$50.2M
Q2 25
$89.4M
$47.4M
Q1 25
$85.7M
$52.6M
Q4 24
$94.9M
$68.7M
Q3 24
$88.5M
$45.1M
Q2 24
$85.8M
$44.5M
Q1 24
$86.8M
$51.1M
Net Profit
SCOR
SCOR
TMCI
TMCI
Q4 25
$3.0M
$-9.4M
Q3 25
$453.0K
$-16.3M
Q2 25
$-9.5M
$-17.4M
Q1 25
$-4.0M
$-15.9M
Q4 24
$3.1M
$-501.0K
Q3 24
$-60.6M
$-15.4M
Q2 24
$-1.7M
$-21.2M
Q1 24
$-1.1M
$-18.7M
Gross Margin
SCOR
SCOR
TMCI
TMCI
Q4 25
41.0%
80.6%
Q3 25
40.6%
79.1%
Q2 25
40.6%
79.7%
Q1 25
39.6%
79.7%
Q4 24
42.4%
80.7%
Q3 24
41.2%
80.1%
Q2 24
39.5%
80.2%
Q1 24
42.3%
80.2%
Operating Margin
SCOR
SCOR
TMCI
TMCI
Q4 25
7.0%
-9.5%
Q3 25
1.9%
-31.2%
Q2 25
-1.9%
-35.8%
Q1 25
-2.4%
-29.6%
Q4 24
4.1%
-0.3%
Q3 24
-67.4%
-33.6%
Q2 24
-2.2%
-48.1%
Q1 24
-2.2%
-37.1%
Net Margin
SCOR
SCOR
TMCI
TMCI
Q4 25
3.2%
-15.0%
Q3 25
0.5%
-32.4%
Q2 25
-10.6%
-36.7%
Q1 25
-4.7%
-30.3%
Q4 24
3.3%
-0.7%
Q3 24
-68.5%
-34.1%
Q2 24
-2.0%
-47.7%
Q1 24
-1.2%
-36.5%
EPS (diluted)
SCOR
SCOR
TMCI
TMCI
Q4 25
$9.50
$-0.14
Q3 25
$-0.86
$-0.26
Q2 25
$-2.73
$-0.28
Q1 25
$-1.66
$-0.25
Q4 24
$-0.47
$-0.01
Q3 24
$-12.79
$-0.25
Q2 24
$-1.19
$-0.34
Q1 24
$-1.08
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SCOR
SCOR
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$23.6M
$48.4M
Total DebtLower is stronger
$41.5M
$55.6M
Stockholders' EquityBook value
$111.4M
$87.3M
Total Assets
$407.7M
$190.6M
Debt / EquityLower = less leverage
0.37×
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SCOR
SCOR
TMCI
TMCI
Q4 25
$23.6M
$48.4M
Q3 25
$26.7M
$57.4M
Q2 25
$26.0M
$69.3M
Q1 25
$31.0M
$76.1M
Q4 24
$29.9M
$75.7M
Q3 24
$20.0M
$82.8M
Q2 24
$14.7M
$95.0M
Q1 24
$18.7M
$110.0M
Total Debt
SCOR
SCOR
TMCI
TMCI
Q4 25
$41.5M
$55.6M
Q3 25
$41.4M
$53.5M
Q2 25
$41.3M
$53.5M
Q1 25
$41.3M
$53.4M
Q4 24
$41.2M
$53.3M
Q3 24
$53.2M
Q2 24
$53.2M
Q1 24
$53.1M
Stockholders' Equity
SCOR
SCOR
TMCI
TMCI
Q4 25
$111.4M
$87.3M
Q3 25
$-26.3M
$89.2M
Q2 25
$-21.7M
$97.6M
Q1 25
$-13.5M
$105.3M
Q4 24
$-8.3M
$112.9M
Q3 24
$-2.7M
$104.9M
Q2 24
$45.8M
$112.1M
Q1 24
$51.4M
$126.4M
Total Assets
SCOR
SCOR
TMCI
TMCI
Q4 25
$407.7M
$190.6M
Q3 25
$406.9M
$196.6M
Q2 25
$415.9M
$206.4M
Q1 25
$421.5M
$205.8M
Q4 24
$430.2M
$217.1M
Q3 24
$412.5M
$212.9M
Q2 24
$474.1M
$226.1M
Q1 24
$477.7M
$242.7M
Debt / Equity
SCOR
SCOR
TMCI
TMCI
Q4 25
0.37×
0.64×
Q3 25
0.60×
Q2 25
0.55×
Q1 25
0.51×
Q4 24
0.47×
Q3 24
0.51×
Q2 24
0.47×
Q1 24
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SCOR
SCOR
TMCI
TMCI
Operating Cash FlowLast quarter
$3.2M
$-8.0M
Free Cash FlowOCF − Capex
$2.9M
$-10.4M
FCF MarginFCF / Revenue
3.1%
-16.7%
Capex IntensityCapex / Revenue
0.3%
3.8%
Cash ConversionOCF / Net Profit
1.07×
TTM Free Cash FlowTrailing 4 quarters
$21.8M
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SCOR
SCOR
TMCI
TMCI
Q4 25
$3.2M
$-8.0M
Q3 25
$9.5M
$-9.1M
Q2 25
$932.0K
$-3.0M
Q1 25
$9.1M
$4.2M
Q4 24
$-10.0M
$-4.2M
Q3 24
$12.5M
$-11.8M
Q2 24
$8.7M
$-13.9M
Q1 24
$6.9M
$-7.2M
Free Cash Flow
SCOR
SCOR
TMCI
TMCI
Q4 25
$2.9M
$-10.4M
Q3 25
$9.4M
$-11.9M
Q2 25
$787.0K
$-7.8M
Q1 25
$8.7M
$655.0K
Q4 24
$-10.3M
$-7.3M
Q3 24
$12.4M
$-14.7M
Q2 24
$8.5M
$-15.6M
Q1 24
$6.6M
$-11.1M
FCF Margin
SCOR
SCOR
TMCI
TMCI
Q4 25
3.1%
-16.7%
Q3 25
10.5%
-23.7%
Q2 25
0.9%
-16.5%
Q1 25
10.1%
1.2%
Q4 24
-10.8%
-10.6%
Q3 24
14.0%
-32.6%
Q2 24
10.0%
-35.2%
Q1 24
7.6%
-21.8%
Capex Intensity
SCOR
SCOR
TMCI
TMCI
Q4 25
0.3%
3.8%
Q3 25
0.1%
5.6%
Q2 25
0.2%
10.1%
Q1 25
0.4%
6.7%
Q4 24
0.2%
4.5%
Q3 24
0.1%
6.4%
Q2 24
0.2%
3.9%
Q1 24
0.3%
7.7%
Cash Conversion
SCOR
SCOR
TMCI
TMCI
Q4 25
1.07×
Q3 25
20.96×
Q2 25
Q1 25
Q4 24
-3.19×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SCOR
SCOR

Transferred Over Time$77.1M83%
Research Insight Solutions$14.6M16%
Related Party$2.5M3%

TMCI
TMCI

Segment breakdown not available.

Related Comparisons